# OnCo record gabriel-hortobagyi (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/gabriel-hortobagyi/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "gabriel-hortobagyi" ;
  schema:name "Gabriel N. Hortobagyi"@en ;
  schema:description "Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease."@en ;
  schema:url <https://onco.cc/people/gabriel-hortobagyi/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib> ;
  onco:tag "breast", "trialist" ;
  schema:jobTitle "Professor of Breast Medical Oncology, MD Anderson Cancer Center" ;
  schema:sameAs <https://orcid.org/0000-0002-4873-4412> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/ribociclib/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:trials <https://onco.cc/trials/monaleesa-2/>, <https://onco.cc/trials/natalee/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-natalee-nejm-2024/> ;
  schema:affiliation <https://onco.cc/institutions/md-anderson/> .